Übersicht
- Teva Pharmaceutical IndustriesAktie883035
- Teva Pharmaceutical IndustriesAktie906517
- Teva Pharmaceutical Unternehmensanleihe 6,15 % bis 02/36AnleiheA0GMZX
- Teva Pharmaceutical Unternehmensanleihe 4,375 % bis 05/30AnleiheA3KYRP
- Teva Pharmaceutical Unternehmensanleihe 1,00 % bis 07/25AnleiheA1VQDJ
- Optionsscheine auf Teva Pharmaceutical IndustriesOpt.schein580
- Knock-Outs auf Teva Pharmaceutical IndustriesKnock-Out497
- Zertifikate auf Teva Pharmaceutical IndustriesZertifikat400
- UroGen Pharma Files Patent Infringement Action Against Teva PharmaceuticalsNachricht03.04.24
- Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024Nachricht01.06.24
- Teva to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNachricht04.06.24
- Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S.Nachricht21.05.24
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)Nachricht16.04.24
- Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S.Nachricht21.05.24
- Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S.Nachricht21.05.24
- Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious TargetsNachricht02.05.24
- Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaNachricht08.05.24
- Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaNachricht08.05.24
- Teva Announces AUSTEDO XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)Nachricht30.05.24
- Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO (deutetrabenazine) TabletsNachricht16.04.24
- Teva Confirms Efficacy and Safety of AJOVY (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in ChinaNachricht11.04.24
Forum
Nachrichten
04.06.24 | Nachricht | |
03.06.24 | Nachricht | |
03.06.24 | Nachricht | |
01.06.24 | Nachricht | |
01.06.24 | Nachricht |